TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest in Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%
Brief Summary: Patients with reduced left ventricular function are at an increased perioperative risk and often need prolonged postoperative treatment on intensive care units. A significant portion of these patients require postoperative pacing. Right ventricular pacing has been shown to be hemodynamically deleterious The aim of this study is to determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF≤ 45%), is hemodynamically favourable.


Options:
A: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: BIO-K+ CL-1285; Type: ACTIVE_COMPARATOR; Interventions: Other: BIO-K+ CL-1285® | Arm Label: BIO-K+ CL-1285® & placebo; Type: OTHER; Interventions: Other: BIO-K+ CL-1285®, Other: Placebo | Intervention Type: OTHER; Name: BIO-K+ CL-1285®; Assigned to Arm(s): BIO-K+ CL-1285, BIO-K+ CL-1285® & placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): BIO-K+ CL-1285® & placebo, Placebo
D: Arm Label: Saccharomyces boulardii; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saccharomyces boulardii | Arm Label: Microcristallin cellulose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Microcristallin cellulose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock
Brief Summary: The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency.


Options:
A: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
B: Arm Label: Drotrecogin alfa (activated); Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:moderate protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:severe protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Alternative therapy:moderate protein C deficiency, Alternative therapy:severe protein C deficiency, Standard therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Efficacy and the Safety of Insulin Detemir and Insulin NPH as add-on to Current OHA Therapy in Subjects With type2 Diabetes Mellitus
Brief Summary: This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in type 2 diabetes when added to current OHA treatment.


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
B: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir
C: Arm Label: NPH insulin + insulin glulisine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nph insulin, Drug: Insulin glulisine | Arm Label: NPH insulin + human insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin | Arm Label: Insulin glargine + insulin glulisine; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine, Drug: Insulin glulisine | Arm Label: Insulin Glargine + Human insulin; Type: EXPERIMENTAL; Interventions: Drug: human insulin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: nph insulin; Assigned to Arm(s): NPH insulin + insulin glulisine | Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): Insulin Glargine + Human insulin, NPH insulin + human insulin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine + Human insulin, Insulin glargine + insulin glulisine | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): Insulin glargine + insulin glulisine, NPH insulin + insulin glulisine
D: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen
Brief Summary: This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in subjects with insulin requiring diabetes.


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
B: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir
C: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901) [Lantus], Drug: Glimepiride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: human insulin [NPH] | Intervention Type: DRUG; Name: Insulin Glargine (HOE901) [Lantus]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: human insulin [NPH]; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus
Brief Summary: This trial is conducted in Europe.

The aim of this trial is to investigate the safety and efficacy of insulin detemir combined with oral anti-diabetic drugs (OADs) versus insulin NPH combined with oral anti-diabetic drugs (OADs) in Type 2 mellitus not well controlled on current therapy on blood glucose control.


Options:
A: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: NPH human insulin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2
D: Arm Label: neutral protamine insulin, metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin detemir | Arm Label: insulin detemir, metformin; Type: EXPERIMENTAL; Interventions: Drug: neutral protamine insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): neutral protamine insulin, metformin | Intervention Type: DRUG; Name: neutral protamine insulin; Assigned to Arm(s): insulin detemir, metformin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center, Patient Handling Study of Mometasone Furoate/Formoterol Fumarate MDI With an Integrated Dose Counter in Adolescent and Adult Subjects and Adult With Asthma or COPD
Brief Summary: This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day approximately 12 hours apart) in participants 12 years of age or older, with a diagnosis of persistent asthma or chronic obstructive pulmonary disease (COPD) of at least 12 months. The primary purpose of the study was to evaluate the performance of the MF/F MDI integrated dose counter under normal patient handling conditions.


Options:
A: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS
B: Intervention Type: DRUG; Name: Formoterol Fumurate inhalation solution 20 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg; Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 100/10 mcg BID with dose counter; Type: EXPERIMENTAL; Interventions: Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | Intervention Type: DRUG; Name: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ); Assigned to Arm(s): MF/F MDI 100/10 mcg BID with dose counter
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: German Multicenter EPO Stroke Trial (Phase II/III)
Brief Summary: The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day high-dose, intravenous erythropoietin treatment on functional outcome up to a follow-up of 90 days.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% NaCl | Arm Label: verum; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin alfa | Intervention Type: DRUG; Name: recombinant human erythropoietin alfa; Assigned to Arm(s): verum | Intervention Type: DRUG; Name: 0.9% NaCl; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Delirium in Critically Ill Patients in a Dutch University Hospital
Brief Summary: The objective of this study is to determine the incidence of delirium in adults patients who are admitted at the critical care unit of a Dutch University Hospital.

The primary aim is to determine the incidence of delirium and to determine risk factors for this group of patients to develop a prediction model.

A secondary aim is to find differences between delirious patients and non-delirious patients on different aspects of diagnostics, treatment and care, outcome, length of stay, and inflammation.

According to Dutch law, the need to obtain informed consent was waived by the Committee on Research Involving Human Subjects (CMO) of Nijmegen for this observational study (2007/283).


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine
B: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A
C: Arm Label: Dynamic light; Type: EXPERIMENTAL; Interventions: Other: Dynamic Light | Arm Label: Normal Light; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dynamic Light; Assigned to Arm(s): Dynamic light
D: Arm Label: Non-sedation; Type: EXPERIMENTAL; Interventions: Other: Non-sedation | Arm Label: Sedation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control: Sedation | Intervention Type: OTHER; Name: Non-sedation; Assigned to Arm(s): Non-sedation | Intervention Type: OTHER; Name: Control: Sedation; Assigned to Arm(s): Sedation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III: The Study of Acid Reflux in Children With Asthma
Brief Summary: Many individuals with asthma also experience gastroesophageal reflux disease (GERD), a condition in which excess stomach acid flows backwards into the esophagus. This study will evaluate the effectiveness of lansoprazole, a medication commonly used to treat GERD in improving asthma control and reducing symptoms in children with poorly controlled asthma.


Options:
A: Arm Label: Lansoprazole; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Lansoprazole; Assigned to Arm(s): Lansoprazole | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Lansoprazole; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Lansoprazole; Assigned to Arm(s): Lansoprazole | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching placebo
C: Arm Label: Esomeprazole 40 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Esomeprazole 40 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg twice daily | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole 40 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo for esomeprazoe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo proton pump inhibitor | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo proton pump inhibitor; Assigned to Arm(s): Placebo for esomeprazoe

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti TNFa Treatment for Deep Endometriosis Associated Pain : a Randomised Placebo Controlled Trial.
Brief Summary: Deep endometriosis associated pain is believed to be caused by inflammation. Anti TNFa has been proved to be an effective treatment for other inflammation related conditions as Crohn's disease Endometriosis is associated with an inflammatory response in the pelvis, which is mediated by a number of cytokines including TNF-α. It has therefore been suggested that infliximab, an anti-TNF-α monoclonal antibody, might relieve pain in affected women.


Options:
A: Arm Label: Gabapentin preoperatively; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Active placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diphenhydramine | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin preoperatively | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Active placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ropivacaine, ketorelac and epinephrine | Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: ropivacaine, ketorelac and epinephrine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): P
C: Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: anti TNFa monoclonal antibody - Infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: anti TNFa monoclonal antibody - Infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)
Brief Summary: The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: lisinopril, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: HCTZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrochlorothiazide | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): HCTZ | Intervention Type: DRUG; Name: nifedipine, long acting; Assigned to Arm(s): Candesartan, Lisinopril | Intervention Type: DRUG; Name: metoprolol, long-acting; Assigned to Arm(s): Candesartan, Lisinopril
C: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.
Brief Summary: The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy. The safety of Macugen compared to standard of care laser will also be evaluated.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
C: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
D: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A

Answer: C